10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Fitness Loss under Amino Acid Starvation in Artemisinin-Resistant Plasmodium falciparum Isolates from Cambodia

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Artemisinin is the most rapidly effective drug for Plasmodium falciparum malaria treatment currently in clinical use. Emerging artemisinin-resistant parasites pose a great global health risk. At present, the level of artemisinin resistance is still relatively low with evidence pointing towards a trade-off between artemisinin resistance and fitness loss. Here we show that artemisinin-resistant P. falciparum isolates from Cambodia manifested fitness loss, showing fewer progenies during the intra-erythrocytic developmental cycle. The loss in fitness was exacerbated under the condition of low exogenous amino acid supply. The resistant parasites failed to undergo maturation, whereas their drug-sensitive counterparts were able to complete the erythrocytic cycle under conditions of amino acid deprivation. The artemisinin-resistant phenotype was not stable, and loss of the phenotype was associated with changes in the expression of a putative target, Exp1, a membrane glutathione transferase. Analysis of SNPs in haemoglobin processing genes revealed associations with parasite clearance times, suggesting changes in haemoglobin catabolism may contribute to artemisinin resistance. These findings on fitness and protein homeostasis could provide clues on how to contain emerging artemisinin-resistant parasites.

          Related collections

          Most cited references39

          • Record: found
          • Abstract: found
          • Article: not found

          Qinghaosu (artemisinin): the price of success.

          N. White (2008)
          Artemisinin and its derivatives have become essential components of antimalarial treatment. These plant-derived peroxides are unique among antimalarial drugs in killing the young intraerythrocytic malaria parasites, thereby preventing their development to more pathological mature stages. This results in rapid clinical and parasitological responses to treatment and life-saving benefit in severe malaria. Artemisinin combination treatments (ACTs) are now first-line drugs for uncomplicated falciparum malaria, but access to ACTs is still limited in most malaria-endemic countries. Improved agricultural practices, selection of high-yielding hybrids, microbial production, and the development of synthetic peroxides will lower prices. A global subsidy would make these drugs more affordable and available. ACTs are central to current malaria elimination initiatives, but there are concerns that tolerance to artemisinins may be emerging in Cambodia.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria

            Artemisinins are the corner stone of anti-malarial drugs 1 . Emergence and spread of resistance to them 2–4 raises risk of wiping out recent gains achieved in reducing world-wide malaria burden and threatens future malaria control and elimination on a global level. Genome wide association studies (GWAS) have revealed parasite genetic loci associated with artemisinin resistance 5–10 . However, there is no consensus on biochemical targets of artemisinin. Whether and how these targets interact with genes identified by GWAS, remains unknown. Here we provide biochemical and cellular evidence that artemisinins are potent inhibitors of Plasmodium falciparum phosphatidylinositol-3-kinase (PfPI3K), revealing an unexpected mechanism of action. In resistant clinical strains, increased PfPI3K was associated with the C580Y mutation in P. falciparum Kelch13 (PfKelch13), a primary marker of artemisinin resistance. Polyubiquitination of PfPI3K and its binding to PfKelch13 were reduced by PfKelch13 mutation, which limited proteolysis of PfPI3K and thus increased levels of the kinase as well as its lipid product phosphatidylinositol 3-phosphate (PI3P). We find PI3P levels to be predictive of artemisinin resistance in both clinical and engineered laboratory parasites as well as across non-isogenic strains. Elevated PI3P induced artemisinin resistance in absence of PfKelch13 mutations, but remained responsive to regulation by PfKelch13. Evidence is presented for PI3P-dependent signaling, where transgenic expression of an additional kinase confers resistance. Together these data present PI3P as the key mediator of artemisinin resistance and the sole PfPI3K as an important target for malaria elimination.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Chloroquine-resistant malaria.

              The development of chloroquine as an antimalarial drug and the subsequent evolution of drug-resistant Plasmodium strains had major impacts on global public health in the 20th century. In P. falciparum, the cause of the most lethal human malaria, chloroquine resistance is linked to multiple mutations in PfCRT, a protein that likely functions as a transporter in the parasite's digestive vacuole membrane. Rapid diagnostic assays for PfCRT mutations are already employed as surveillance tools for drug resistance. Here, we review recent field studies that support the central role of PfCRT mutations in chloroquine resistance. These studies suggest chloroquine resistance arose in > or = 4 distinct geographic foci and substantiate an important role of immunity in the outcomes of resistant infections after chloroquine treatment. P. vivax, which also causes human malaria, appears to differ from P. falciparum in its mechanism of chloroquine resistance. Investigation of the resistance mechanisms and of the role of immunity in therapeutic outcomes will support new approaches to drugs that can take the place of chloroquine or augment its efficiency.
                Bookmark

                Author and article information

                Contributors
                thanat.cho@mahidol.edu
                Journal
                Sci Rep
                Sci Rep
                Scientific Reports
                Nature Publishing Group UK (London )
                2045-2322
                22 August 2018
                22 August 2018
                2018
                : 8
                : 12622
                Affiliations
                [1 ]ISNI 0000 0004 1937 0490, GRID grid.10223.32, Genomics and Evolutionary Medicine Unit (GEM), , Center of Excellence in Malaria Research, Faculty of Tropical Medicine, Mahidol University, ; Bangkok, Thailand
                [2 ]GRID grid.416009.a, Division of Medical Genetics, Department of Medicine, , Faculty of Medicine, Siriraj Hospital, ; Bangkok, Thailand
                [3 ]ISNI 0000 0004 1937 0490, GRID grid.10223.32, Molecular Medicine Graduate Program, Faculty of Science, , Mahidol University, ; Bangkok, Thailand
                [4 ]ISNI 0000 0004 1937 0490, GRID grid.10223.32, Department of Biochemistry, Faculty of Science, , Mahidol University, ; Bangkok, Thailand
                [5 ]ISNI 0000 0004 1937 0490, GRID grid.10223.32, Department of Physics, Faculty of Science, , Mahidol University, ; Bangkok, Thailand
                [6 ]ISNI 0000 0004 1937 0490, GRID grid.10223.32, Laboratory Animal Science Unit, Faculty of Tropical Medicine, , Mahidol University, ; Bangkok, Thailand
                [7 ]ISNI 0000 0001 2097 4281, GRID grid.29857.31, Department of Entomology, , Pennsylvania State University, ; University Park, PA USA
                [8 ]ISNI 0000 0004 1937 0490, GRID grid.10223.32, Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, , Mahidol University, ; Bangkok, Thailand
                [9 ]ISNI 0000 0004 1937 0490, GRID grid.10223.32, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, , Mahidol University, ; Bangkok, Thailand
                [10 ]ISNI 0000 0004 1936 8948, GRID grid.4991.5, Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, , University of Oxford, ; Oxford, UK
                [11 ]ISNI 0000 0004 0606 5382, GRID grid.10306.34, Wellcome Sanger Institute, ; Hinxton, UK
                [12 ]ISNI 0000 0004 1936 8948, GRID grid.4991.5, Medical Research Council (MRC) Centre for Genomics and Global Health, , University of Oxford, ; Oxford, UK
                [13 ]ISNI 0000 0004 0606 5382, GRID grid.10306.34, Present Address: Wellcome Sanger Institute, ; Hinxton, UK
                Author information
                http://orcid.org/0000-0002-0739-006X
                http://orcid.org/0000-0002-8338-1974
                http://orcid.org/0000-0001-8060-6771
                http://orcid.org/0000-0003-2876-6203
                Article
                30593
                10.1038/s41598-018-30593-5
                6105667
                30135481
                30181f84-153f-4aa3-8867-312685b102d3
                © The Author(s) 2018

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 3 April 2017
                : 31 July 2018
                Categories
                Article
                Custom metadata
                © The Author(s) 2018

                Uncategorized
                Uncategorized

                Comments

                Comment on this article